In multiple sclerosis anxiety, not depression, is related to gender

Multiple Sclerosis

Volumn 22, Issue 2, 2016, Pages 239-244

  Théaudin, Marie ^a,b   Romero, Kristoffer ^a   Feinstein, Anthony ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b MS Clinic Saint Michael's Hospital   (Canada)

Author keywords

anxiety; depression; gender; Multiple sclerosis

Indexed keywords

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DEPRESSION; DISEASE ASSOCIATION; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PREDICTION; RETROSPECTIVE STUDY; SCORING SYSTEM; SEX DIFFERENCE; ANXIETY; DISEASE COURSE; GENDER; MARRIAGE; SOCIOECONOMICS; ANXIETY DISORDERS; DEPRESSIVE DISORDER; FACTUAL DATABASE; MIDDLE AGED; PREVALENCE; PSYCHOLOGY;

DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ADULT; ANXIETY; ANXIETY DISORDERS; DATABASES, FACTUAL; DEPRESSION; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PREVALENCE; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 84957091627     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515588582     Document Type: Article

References (40)

1. Sadovnick AD, Remick RA, Allen J, et al. Depression and multiple sclerosis. Neurology 1996; 46: 628-632.
2. Patten SB, Beck CA, Williams JVA, et al. Major depression in multiple sclerosis: A population-based perspective. Neurology 2003; 61: 1524-1527.
3. Korostil M, Feinstein A,. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler 2007; 13: 67-72.
4. Dahl OP, Stordal E, Lydersen S, et al. Anxiety and depression in multiple sclerosis. A comparative population-based study in Nord-Trøndelag County, Norway. Mult Scler 2009; 15: 1495-1501
5. Jones KH, Ford DV, Jones PA, et al. A large-scale study of anxiety and depression in people with multiple sclerosis: A survey via the web portal of the UK MS Register. PloS One 2012; 7: e41910.
6. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8-19.
7. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005; 62: 593-602.
8. Lewinsohn PM, Gotlib IH, Lewinsohn M, et al. Gender differences in anxiety disorders and anxiety symptoms in adolescents. J Abnorm Psychol 1998; 107: 109-117.
9. Altemus M, Sarvaiya N, Neill Epperson C,. Sex differences in anxiety and depression clinical perspectives. Front Neuroendocrinol 2014; 35: 320-330.
10. Da Silva AM, Vilhena E, Lopes A, et al. Depression and anxiety in a Portuguese MS population: Associations with physical disability and severity of disease. J Neurol Sci 2011; 306: 66-70.
11. Galeazzi GM, Ferrari S, Giaroli G, et al. Psychiatric disorders and depression in multiple sclerosis outpatients: Impact of disability and interferon beta therapy. Neurol Sci 2005; 26: 255-262.
12. Chwastiak L, Ehde DM, Gibbons LE, et al. Depressive symptoms and severity of illness in multiple sclerosis: Epidemiologic study of a large community sample. Am J Psychiatry 2002; 159: 1862-1868.
13. Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: A longitudinal study. Lancet Neurol 2006; 5: 932-936.
14. Westerlind H, Boström I, Stawiarz L, et al. New data identify an increasing sex ratio of multiple sclerosis in Sweden. Mult Scler 2014; 20: 1578-1583.
15. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
16. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
17. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria.". Ann Neurol 2005; 58: 840-846.
18. Zigmond AS, Snaith RP,. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370.
19. Honarmand K, Feinstein A,. Validation of the Hospital Anxiety and Depression Scale for use with multiple sclerosis patients. Mult Scler 2009; 15: 1518-1524.
20. Leach LS, Christensen H, Mackinnon AJ, et al. Gender differences in depression and anxiety across the adult lifespan: The role of psychosocial mediators. Soc Psychiatry Psychiatr Epidemiol 2008; 43: 983-998.
21. Eaton WW, Kalaydjian A, Scharfstein DO, et al. Prevalence and incidence of depressive disorder: The Baltimore ECA follow-up, 1981-2004. Acta Psychiatr Scand 2007; 116: 182-188.
22. Crawford JR, Henry JD, Crombie C, et al. Normative data for the HADS from a large non-clinical sample. Br J Clin Psychol 2001; 40: 429-434.
23. Formanek R, Gurian A,. Women and depression: A lifespan perspective. New York: Springer Pub Co., 1987, p. 306.
24. Pujol J, Bello J, Deus J, et al. Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis. Neurology 1997; 49: 1105-1110.
25. Feinstein A, Roy P, Lobaugh N, et al. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 2004; 62: 586-590.
26. Bakshi R, Czarnecki D, Shaikh ZA, et al. Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Neuroreport 2000; 11: 1153-1158.
27. Feinstein A, O'Connor P, Akbar N, et al. Diffusion tensor imaging abnormalities in depressed multiple sclerosis patients. Mult Scler 2010; 16: 189-196.
28. Foley FW, Traugott U, LaRocca NG, et al. A prospective study of depression and immune dysregulation in multiple sclerosis. Arch Neurol 1992; 49: 238-244.
29. Pucak ML, Carroll KAL, Kerr DA, et al. Neuropsychiatric manifestations of depression in multiple sclerosis: Neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of immune-mediated depression. Dialogues Clin Neurosci 2007; 9: 125-139.
30. Schiepers OJG, Wichers MC, Maes M,. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 201-217.
31. Williams A, Piaton G, Lubetzki C,. Astrocytes-friends or foes in multiple sclerosis? Glia 2007; 55: 1300-1312.
32. Gold SM, Kern KC, O'Connor MF, et al. Smaller cornu ammonis 2-3/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms. Biol Psychiatry 2010; 68: 553-559.
33. Galetta SL, Markowitz C,. US FDA-approved disease-modifying treatments for multiple sclerosis: Review of adverse effect profiles. CNS Drugs 2005; 19: 239-252.
34. Turner AP, Williams RM, Sloan AP, et al. Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis. Rehabil Psychol 2009; 54: 116-121.
35. Kirzinger SS, Jones J, Siegwald A, et al. Relationship between disease-modifying therapy and depression in multiple sclerosis. Int J MS Care 2013; 15: 107-112.
36. Arnett PA, Randolph JJ,. Longitudinal course of depression symptoms in multiple sclerosis. J Neurol Neurosurg Psychiatry 2006; 77: 606-610.
37. Pandya R, Patten S,. Depression in multiple sclerosis associated with interferon beta-1a (Rebif). Can J Psychiatry 2002; 47: 686.
38. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 655-661.
39. Feinstein A, O'Connor P, Gray T, et al. The effects of anxiety on psychiatric morbidity in patients with multiple sclerosis. Mult Scler 1999; 5: 323-326.
40. José Sá M,. Psychological aspects of multiple sclerosis. Clin Neurol Neurosurg 2008; 110: 868-877.